Technical Articles

Among the four FGFR family members, FGFR4 alone resides in the liver and binds the KLB co-receptor. From an industry perspective, this article dissects the FGF19 axis, its association with hepatocellular carcinoma and the design logic of selective in

The FGFR4 door opens only when both keys—FGF19 and KLB—are inserted at the same time. This article walks through the four-step assembly of the FGF19-FGFR4-KLB ternary complex and the full process of signal entry.

Hepatocellular carcinoma is the most common primary liver cancer and has limited response to conventional therapies. Adoptive T cell therapies (such as TCR-T therapy) have shown significant efficacy in hematologic malignancies.